

# PERSONALIZED THERAPY for PATIENTS with ANTIBODY-MEDIATED REJECTION

## TUESDAY, 17 SEPTEMBER 2019

**Registration**  
16:35 – 17:05

**Symposium and Panel Discussion**  
17:05 – 18:35

Bella Center Copenhagen  
Rm C1M2  
Copenhagen, Denmark

Supported by an independent educational grant from CSL Behring.

**REGISTER ONLINE** [www.RMEI.com/ESOT2019](http://www.RMEI.com/ESOT2019)

### PATIENT-CENTRIC SYMPOSIUM

Don't miss this engaging panel discussion, enhanced with evidence-based cases on antibody-mediated rejection (AMR) in solid organ transplant (SOT) patients. Faculty will be joined by a renal transplant patient with experience in AMR, to add their perspective on the care delivery experience.

**TUESDAY, 17 SEPTEMBER 2019**

### FACULTY



**Klemens Budde, MD (Chair)**  
*Senior Consultant*  
Department of Nephrology and Intensive Care  
Charité Universitätsmedizin  
Berlin, Germany



**Georg Böhmig, MD**  
*Associate Professor*  
Division of Nephrology and Dialysis  
Department of Medicine III  
Medical University of Vienna  
Vienna, Austria



**Fritz Diekmann, MD**  
*Associate Professor*  
*Chief, Kidney Transplant Unit*  
Hospital Clinic de Barcelona  
Barcelona, Spain



**Michael Mengel, MD**  
*Professor and Chair*  
Department of Laboratory Medicine and Pathology  
University of Alberta  
Edmonton, Canada

### EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

- Describe the pathophysiology of antibody-mediated rejection (AMR), including the significance of the activation of the complement system and cytokine pathways in order to effectively and aggressively institute treatment
- Discuss existing and emerging treatment options for AMR, including anti-complement and anti-cytokine strategies
- Select appropriate therapeutic agents and protocols to treat AMR and prolong allograft survival

### PROGRAM AGENDA

16:35 – 17:05 **Registration & Welcome Refreshments**

17:05 – 17:10 **Welcome and Introductions**  
*Klemens Budde, MD*

17:10 – 17:35 **Clinical Case 1 – Patient with Active Acute AMR**  
*Klemens Budde, MD; Michael Mengel, MD; and Panel (including AMR Patient)*  
*Audience Q&A*

17:35 – 18:00 **Clinical Case 2 – Patient with Chronic Active AMR**  
*Georg Böhmig, MD; Michael Mengel, MD; and Panel (including AMR Patient)*  
*Audience Q&A*

18:00 – 18:25 **Clinical Case 3 – Patient with Refractory AMR**  
*Fritz Diekmann, MD; Michael Mengel, MD; and Panel (including AMR Patient)*  
*Audience Q&A*

18:25 – 18:35 **Audience Q&A, Closing Remarks**  
*Panel*

### TARGET AUDIENCE

Clinicians who manage antibody-mediated rejection (AMR) in patients who undergo solid organ transplant (SOT).

### PROVIDER STATEMENT

This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with Advancing Knowledge in Healthcare (AKH) Inc. All faculty and planner conflicts of interest were identified and resolved and AKH has reviewed the content and determined it to be fair, balanced, and without commercial bias.

### STATEMENT OF SUPPORT

This activity is supported by an independent educational grant from CSL Behring.

### FEE STATEMENT

There is no fee for this educational activity.

### QUESTIONS?

Please contact Stephanie Kielt at [skielt@rmei.com](mailto:skielt@rmei.com) if you have any questions.